Adjuvants—substances known to enhance our immune response—are a key component of many existing vaccines. And while vaccines are one of the most powerful tools we have to fight pandemics, ensuring widespread access to efficacious vaccines continues to be a major challenge around the world.
SaponiQx, a new subsidiary announced today by Agenus, plans to use Ginkgo’s platform to drive innovation in novel adjuvant discovery and vaccine design.
Their efforts will focus on building an innovative adjuvant platform to deliver both sustainable manufacturing approaches and a secure supply of known adjuvants, as well as discover novel adjuvants and develop new, more effective vaccines utilizing optimized antigen-adjuvant pairings.
Ginkgo’s experience in metabolic engineering, enzymatic diversification, and process optimization can be applied to discover novel adjuvants and improve current manufacturing processes that can then be applied toward developing better-integrated vaccines. We’re proud that our platform is being used by companies across the vaccine supply chain to develop and manufacture the materials necessary for life-saving vaccines.
Garo Armen, CEO and Chairman of Agenus and Executive Chairman of SaponiQx, had this to say: “Agenus is pleased for SaponiQx to collaborate with Ginkgo Bioworks to develop its novel saponin products from sustainably sourced raw materials, with a goal to meet the current demands placed on the vaccine industry for pandemic vaccines. The QS21 Stimulon™ adjuvant has shown long term efficacy and long-term protection in both commercially launched and experimental vaccines.”
